Exelixis

Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis
Motley Fool
Sat, 05/24/14 - 09:50 am
Ariad Pharmaceuticals
Exelixis
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Motley Fool
Fri, 05/2/14 - 08:37 am
earnings
Exelixis
1 of These 3 Cratering Biotechs is a Buy
Motley Fool
Sun, 04/20/14 - 09:27 am
Halozyme
Exelixis
Vivus
Is This the Year Exelixis Excels?
Morningstar
Fri, 03/28/14 - 10:06 am
Exelixis
Cometriq
prostate cancer
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis
TheStreet.com
Wed, 03/26/14 - 12:38 pm
prostate cancer
Exelixis
cabozantinib
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data
Motley Fool
Thu, 02/20/14 - 05:31 pm
Exelixis
earnings
What's Next for This Biotech?
Motley Fool
Wed, 11/6/13 - 03:32 pm
Exelixis
Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013
Yahoo/BusinessWire
Sat, 09/28/13 - 11:58 am
metastatic melanoma
melanoma
Exelixis
Cobimetinib
Exelixis achieves enrollment target for phase 3 trial of cabozantinib
Yahoo/Fly on the Wall
Thu, 09/26/13 - 08:19 am
Exelixis
cabozantinib
metastatic castration-resistant prostate cancer
An Excellent Investment in the Biotech Space?
Motley Fool
Sat, 09/21/13 - 10:08 am
Cometriq
medullary thyroid cancer
Exelixis
Will the Exelixis Hype Catch Up to Its Valuation?
Motley Fool
Tue, 09/17/13 - 11:04 am
Exelixis
Cometriq
medullary thyroid cancer
The Best- And Worst-Performing Biotech Stocks July 19 To July 26
Forbes
Mon, 07/29/13 - 12:27 pm
TearLab
Array Biopharma
Furiex Pharmaceuticals
InterMune
Prosensa
Boston Scientific
Orexigen
Momenta
Ironwood
INSYS Therapeutics
Sequenom
OncoMed
Abraxis
Sarepta
Epizyme
Tesaro
Synta Pharmaceuticals
Bluebird Bio
Exelixis
Lexicon Pharmaceuticals
Intercept Pharma
GTx
Exelixis Presents Cometriq (cabozantinib) Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer
Yahoo/BusinessWire
Sun, 06/2/13 - 11:41 am
Exelixis
Cometriq
thyroid cancer
medullary thyroid cancer
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire
Sat, 06/1/13 - 12:17 pm
Exelixis
cabozantinib
prostate cancer
Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players
Motley Fool
Mon, 04/29/13 - 05:24 pm
thyroid cancer
Caprelsa
AstraZeneca
Cometriq
Exelixis
Nexavar
Bayer
ONYX Pharmaceuticals
Where Is Exelixis In The Cancer Therapeutics Market?
Seeking Alpha
Mon, 04/1/13 - 11:01 am
Exelixis
cabozantinib
Cometriq
cancer
Why Exelixis Is Ready to Rebound
Motley Fool
Sun, 03/3/13 - 11:48 am
Exelixis
Exelixis Earnings: Everything You Must Know Now
Wall St. Cheat Sheet
Fri, 02/22/13 - 11:09 am
earnings
Exelixis
What's Ahead for Exelixis?
Motley Fool
Sun, 02/3/13 - 11:36 am
Exelixis
Genentech takes Exelixis drug into Phase III melanoma trial
Bizjournals.com
Thu, 01/17/13 - 10:19 am
Exelixis
Genentech
melanoma
Roche
Zelboraf
GDC-0973

Pages